|
|
|
|
|
14.11.25 - 05:15
|
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to the Company entering into subscription agreements with investors in the offering, if any, and certain customary closing conditions including, but not limited to, the receipt of all necessary approvals, including approval from the Toronto Stock Exchange (“TSX”)....
|
|
|
14.11.25 - 05:12
|
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 700,000 common shares on the same terms and conditions. Fennec anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) will be approximately $35,000,000, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on November 17, 2025, subject to customary closing conditions....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.08.25 - 13:15
|
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
